Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer

British Journal of Cancer

Volumn 80, Issue 1-2, 1999, Pages 273-278

  Protheroe, A S ^a   Banks, R E ^a   Mzimba, M ^a   Porter, W H ^c   Southgate, J ^a   Singh, P N ^a   Bosomworth, M ^a,b   Harnden, P ^a,b   Smith, P H ^a   Whelan, P ^a   Selby, P J ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c Department of Pathology St James's University Hospital ^*

Author keywords

Bladder; Cancer; E cadherin; Soluble adhesion molecules; Urine

Indexed keywords

CREATININE; UVOMORULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; URINE;

EID: 0032921526     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690351     Document Type: Article

References (48)

1. Banks RE, Porter WH, Whelan P, Smith PH and Selby PJ (1995) Soluble forms of the adhesion molecule E-cadherin in urine. J Clin Path 48: 179-180
2. Becker KF and Hofler H (1995) Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas. J Natl Cancer Inst 87: 1082-1084
3. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HFM, Debrugne FMJ and Schalken JA (1993) Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumours. Cancer Res 53: 3241-3245
4. Caliskan M, Turkeri LN, Mansuroglu B, Toktas G, Aksoy B, Uncluer E and Akdas A (1997) Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer. Br J Urol 79: 373-377
5. Cancer Research Campaign Factsheet 9.1 (1997) Cancer Research Campaign: London
6. Damsky CH, Richa J, Solter D, Knudsen K and Buck CA (1983) Identification and purification of a cell surface glycoprotein mediating intercellular adhesion in embryonic and adult tissue. Cell 34: 455-466
7. D'Hallewin MA and Baert L (1996) Initial evaluation of the bladder tumour antigen test in superficial bladder cancer. J Urol 155: 475-476
8. Dyson EH, Will EJ, Davidson AM, O'Malley AH, Shepard HT and Jones RG (1992) Use of the urinary protein creatinine index to assess proteinuria in renal transplant patients. Nephrol Dial Transplant 7: 450-452
9. Esrig D, Elmajian D, Groshen S, Freeman J, Stein J, Chen SC, Nichols P, Skinner D, Jones P and Cote R (1994) Accumulation of nuclear p53 and tumour progression in bladder cancer. N Engl J Med 331: 1259-1264
10. Gearing AJH and Newman W (1993) Circulating adhesion molecules in disease. Immunol Today 14: 506-512
11. Gohji K, Fujimoto N, Ohkawa J, Fujii A and Nakajima M (1998) Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer 77: 650-655
12. Griffiths TRL, Brotherick I, Bishop RI, White MD, McKenna DM, Horne CHW, Shenton BK, Neal DE and Mellon JK (1996) Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer 74: 579-584
13. Hemmingsen L, Rasmussen F, Skaarup P and Wolf H (1981) Urinary protein profiles in patients with urothelial bladder tumours. Br J Urol 53: 324-329
14. Hermanek P and Sobin LH (eds) (1987) UICC TNM Classification of Malignant Tumours, 4th edn, pp. 65-67. Springer Verlag: Berlin
15. Hiraguri S, Godfrey T, Nakamura H, Graff J, Collins C, Shayesteh L, Doggett N, Johnson K, Wheelock M, Herman J, Baylin S, Pinkel D and Gray J (1988) Mechanisms of inactivation of E-Cadherin in breast cancer cell lines. Cancer Res 58: 1972-1977
16. Hudson MA and Catalona WJ (1996) Urothelial tumours of the bladder, upper tracts and prostate. In Adult and Paediatric Urology. Gillenwater JY, Grayhack JT, Howards SS and Duckett JW (eds). pp. 643-694. Mosby: St Louis, MO
17. Johansson B (1975) Urinary protein patterns in patients with uroepithelial tumours. Scand J Urol Nephrol 9: 221-225
18. Johansson B and Kistner S (1975) Proteinuria in patients with uroepithelial tumours wilh special regard to tumour size, clinical staging and grade of malignancy. Scand J Urol Nephrol 9: 45-49
19. Jones LW, Levin A and Fudenberg HH (1975) Glomerular antigen complexes associated with transitional cell carcinoma. Surg Gynecol Obstet 140: 896-898
20. Kanai Y, Oda T, Tsuda H, Ochiai A and Hirohashi S (1994) Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast. Jpn J Cancer Res 85: 1035-1039
21. Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M and Kagawa S (1998) Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 82: 1359-1366
22. Katayama M, Hirai S, Kamihagi K, Nakagawa K, Yasumoto M and Kato I (1994a) Soluble E-cadherin fragments increased in circulation of cancer patients. Br J Cancer 69: 580-585
23. Katayama M, Hirai S, Yasumoto M, Nishikawa K, Nagata S, Otsuka M, Kamihagi K and Kato I (1994b) Soluble fragments of E-cadherin cell adhesion molecule increase in urinary excretion of cancer patients, potentially indicating its shedding from epithelial tumour cells. Int J Oncol 5: 1049-1057
24. Kinoshita H, Ogawa O, Kakehi Y, Mishina M, Mitsumori K, Itoh N, Yamada H, Terachi T and Yoshida O (1997) Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst 89: 724-730
25. Leyh H, Hall R, Mazeman E and Blumenstein B (1997) Comparison of the BARD BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. Urology 50: 49-53
26. Lipponen PK and Eskelinen MJ (1995). Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol 121: 303-308
27. Mao L, Schoenberg M, Scicchitano M, Erozan Y, Merlo A, Schwab D and Sidransky D (1996) Molecular detection of primary bladder cancer by microsatellite analysis. Science 271: 659-662
28. Matsuura K, Kawanishi J, Fujii S, Imamura M, Hiranos S, Takeichi M and Niitsu Y (1992) Altered expression of E-cadherin in gastric cancer tissue and carcinomatous fluid. Br J Cancer 66: 1122-1130
29. Mitchell S, Sheldon T and Shaw A (1993) Quantification of proteinuria: a re-evaluation of the protein/creatinine ratio for elderly subjects. Age Ageing 22: 443-449
30. Mostofi FK, Sobin LH and Torloni H (1973) Histological typing of urinary bladder tumours. In International Histological Classification of Tumours, 10: World Health Organization: Geneva
31. O'Brien P, Gozzo J, Cronin W and Monaco A (1980) Qualitative analysis of proteinuria associated with bladder cancer. Invest Urol 17: 28-32
32. O'Brien P, Gozzo JJ and Monaco AP (1981) Urinary proteins as biological markers: bladder cancer diagnosis versus urinary tract infection. J Urol 124: 802-803
33. Otto T, Birchmeier W, Schmidt U, Hinke A, Schipper J, Rubben H and Raz A (1994) Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res 54: 3120-3123
34. 2+ binding site of uvomorulin abolish adhesive function. Cell 63: 1033-1038
35. Parmar MKB, Freedman LS, Hargreave TB and Tolley DA (1989) Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 142: 284-288
36. Reading J, Hall RR and Parmar MKB (1995) The application of a prognostic factor analysis for Ta.TI bladder cancer in routine urological practice. Br J Urol 75: 604-607
37. Rock RC, Walker WG and Jennings CD (1986) Nitrogen metabolites and renal function. In Textbook of Clinical Chemistry, Tietz NW (ed), pp. 1254-1316. WB Saunders: Philadelphia
38. Ross JS, Del Rosario AD, Figge HL, Sheehan C, Fisher HAG and Bui HX (1995) E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder. Hum Pathol 26: 940-944
39. Sarosdy M, deVERE White R, Soloway M, Sheinfeld J, Hudson M, Schellhammer P, Jarowenko M, Adams G and Blumenstein B (1995) Results of a multicentre trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 154: 379-384
40. Shimoyama Y, Nagafuchi A, Fujita S, Gotoh M, Takeichi M, Tsukita S and Hirohashi S (1992) Cadherin dysfunction in a human cancer cell line: possible involvement of loss of α-catenin expression in reduced cell-cell adhesiveness. Cancer Res 52: 5770-5774
41. Soloway M, Briggman J, Carpinito G, Chodak G, Church P, Lamm D, Lange P, Messing E, Pasciak R, Reservitz G, Rukstalis D, Sarosdy M, Stadler W, Thiel R and Hayden C (1996) Use of a new tumour marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156: 363-367
42. Steiner G, Schoenberg MP, Linn JF, Mao L and Sidransky D (1997) Detection of bladder cancer recurrence by microsatellite analysis of urine. Nature Med 3: 621-624
43. Syrigos K, Krausz T, Waxman J, Pandha H, Rowlinson-Busza G, Verne J, Epenetos A and Pignatelli M (1995). E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. Int J Cancer 64: 367-370
44. Takeichi M (1990) Cadherins: a molecular family important in selective cell-cell adhesion. Ann Rev Biochem 59: 237-252
45. Takeichi M (1993) Cadherins in cancer implications for invasion and metastasis. Curr Opin Cell Biol 5: 806-811
46. Tsuji M, Kojima Y, Murakami Y, Kanayama H and Kagawa S (1997) Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br J Urol 79: 367-372
47. Yoshida K, Sugino T, Tahara H, Woodman A, Bolodeoku J, Nargund V, Fellows G, Goodison S, Tahara E and Tarin D (1997) Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 79: 362-369
48. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T and Hirohashi S (1995) Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 92: 7416-7419